Boston Scientific’s Advancement in Its Heart Failure Device Segment
On September 25, 2017, Boston Scientific (BSX) announced the launch of the Resonate family of ICD (implantable cardioverter defibrillator) and CRT-D (cardiac resynchronization therapy defibrillator) systems. The devices feature Boston Scientific’s HeartLogic Heart Failure Diagnostic system and are approved by the FDA for conditional use in the MRI (magnetic resonance imaging) environment.
The devices received the CE Mark in February 2017 and were approved by the FDA in May 2017. For more on the devices’ FDA approval, please read BSX’s Resonate ICD and CRT-D Defibrillators Get US Approval. The devices are expected to be commercially available by late 2017.
Interested in ABT? Don't miss the next report.
Receive e-mail alerts for new research on ABT
The devices enhance the company’s Heart Failure business offerings. The Heart Failure business is a key segment of the company’s Rhythm Management segment.
In 2Q17, global Rhythm Management sales witnessed operational growth of ~2%. The segment also registered a higher-than-expected operating margin in the quarter, driven by the company’s strong operational improvements in the segment.
The major players in the heart failure management market that pose competition to Boston Scientific include Medtronic (MDT), Abbott Laboratories (ABT), and Edwards Lifesciences (EW). Investors seeking diversified exposure to Boston Scientific can consider investing in the Vanguard S&P 500 ETF (VOO), which holds ~0.19% of its portfolio in BSX.
Boston Scientific’s (BSX) newly launched Resonate ICD and CRT-D in the United States features the company’s EnduraLife battery technology and SmartCRT technology. BSX’s SmartCRT technology include its multisite multi-electrode pacing capability.
HeartLogic Diagnostic is also one of the key features of the Resonate devices launched recently that feature MRI capability. For a detailed look at the HeartLogic Diagnostic system, please read Trial Data Affirms Positive Results of HeartLogic Diagnostic Service.
We will discuss the results of late-breaking clinical trial data for the BSX’s HeartLogic Diagnostic in the next article. Boston Scientific has started a series of post-approval clinical trials for evaluating the HeartLogic Diagnostic and has initiated patient enrollment for its Manage-HF study.